Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MannKind Corp (NASDAQ:MNKD)

0.6853
Delayed Data
As of Jan 13
 +0.0392 / +6.07%
Today’s Change
0.41
Today|||52-Week Range
2.24
+7.63%
Year-to-Date
Insulin Drug Offers Hope for MannKind
Jan 12 / TheStreet.com - Paid Partner Content
Is MannKind Corp. Ready to Rebound in 2017?
Jan 09 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close0.65
Today’s open0.67
Day’s range0.66 - 0.72
Volume7,454,260
Average volume (3 months)4,710,314
Market cap$327.8M
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+113.19%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
SRNESorrento Therapeutic...+0.15+2.73%
CRBPCorbus Pharmaceutica...-0.15-1.96%
TRVNTrevena Inc-0.04-0.62%
SVASinovac Biotech Ltd+0.02+0.33%
Data as of 01/13/2017

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$0.03
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer &
Vice President
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts


Search for Jobs